Clinical trialNCT03630211RecruitingPhase 2Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

SponsorPaul SzabolcsEnrollment8Diffuse Sclerosis SystemicInterstitial Lung DiseasePulmonary HypertensionSystemic Sclerosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul Szabolcs, MD
University of Pittsburgh
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital of Pittsburgh of Upmc
Pittsburgh, Pennsylvania, United States
Adam Olson, MDAllison Morris, MD, MSAnnie Im, MDArchana Ramgopal, DODaniel Kass, MDFranziska Rosser, MD, MPHGeoffrey Kurland, MDJoshua Levenson, MDKathryn Torok, MDKirsten Rose-Felker, MDPaul Szabolcs, MDPaulina Horvei, MDRobert Lafyatis, MDRobyn Domsic, MD, MPH
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Alemtuzumab →Lymphocyte immune globulin, anti-thymocyte globulin →Cyclophosphamide →GM-CSFIntravenous immunoglobulinMesna →Rituximab →Thiotepa

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2018
Primary completion: 1 Aug 2028
Completion: 1 Aug 2028
Last update posted: 14 Aug 2026
Registered enrollment: 8
Registry id: NCT03630211

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.